368 related articles for article (PubMed ID: 27533774)
1. VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION.
Ceklic L; Munk MR; Wolf-Schnurrbusch U; Gekkieva M; Wolf S
Retina; 2017 Apr; 37(4):687-693. PubMed ID: 27533774
[TBL] [Abstract][Full Text] [Related]
2. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
Wolf S; Balciuniene VJ; Laganovska G; Menchini U; Ohno-Matsui K; Sharma T; Wong TY; Silva R; Pilz S; Gekkieva M;
Ophthalmology; 2014 Mar; 121(3):682-92.e2. PubMed ID: 24326106
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
4. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
5. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
6. Retinoschisis and intravitreal ranibizumab treatment for myopic choroidal neovascularization.
Huang J; Chen T; Lu Y; Long L; Dai H
Chin Med J (Engl); 2014; 127(11):2053-7. PubMed ID: 24890151
[TBL] [Abstract][Full Text] [Related]
7. Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study.
Amoaku WM; Gale RP; Lotery AJ; Menon G; Sivaprasad S; Petrillo J; Quinn J
PLoS One; 2015; 10(6):e0128403. PubMed ID: 26039355
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients.
Yang X; Dai H
Chin Med J (Engl); 2014; 127(16):2906-10. PubMed ID: 25131225
[TBL] [Abstract][Full Text] [Related]
9. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
Kung YH; Wu TT; Huang YH
Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
[TBL] [Abstract][Full Text] [Related]
10. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
11. OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization.
Ricci F; Staurenghi G; Varano M; Eandi C; Sinibaldi TL; Colombo L; Bartezaghi M; Bassanini S
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):759-768. PubMed ID: 30680452
[TBL] [Abstract][Full Text] [Related]
12. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
Chen C; Yan M; Huang Z; Song YP
Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
[No Abstract] [Full Text] [Related]
13. Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan.
Ohno-Matsui K; Suzaki M; Teshima R; Okami N
Eye (Lond); 2018 Dec; 32(12):1871-1878. PubMed ID: 30158574
[TBL] [Abstract][Full Text] [Related]
14. Two-year outcome of intravitreal injections of ranibizumab for myopic choroidal neovascularization.
Wu TT; Kung YH
J Ocul Pharmacol Ther; 2014 Dec; 30(10):837-41. PubMed ID: 25162313
[TBL] [Abstract][Full Text] [Related]
15. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
[TBL] [Abstract][Full Text] [Related]
16. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
Wu TT; Kung YH
Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of intravitreal ranibizumab for choroidal neovascularization due to pathological myopia with and without a dome-shaped macula.
Cai B; Yang J; Li S; Wang L; Chen L; Li X; Li Z
Medicine (Baltimore); 2017 Dec; 96(50):e9251. PubMed ID: 29390361
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
